<DOC>
	<DOCNO>NCT00445146</DOCNO>
	<brief_summary>The main objective study observe long-term safety elvitegravir ( EVG ) boost ritonavir ( RTV ) combination antiretroviral ( ARV ) agents participant complete prior EVG+RTV treatment study .</brief_summary>
	<brief_title>Safety EVG+RTV Administered With Other Antiretroviral Agents Treatment HIV-1 Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Anti-Retroviral Agents</mesh_term>
	<criteria>Completion prior EVG+RTV treatment study without treatmentlimiting toxicity . Males females childbearing potential must agree utilize effective contraception method . Ability understand sign write informed consent form . Females pregnant breastfeeding . Participation clinical trial without prior approval Sponsor . Any clinical condition prior therapy , opinion investigator , would make subject unsuitable study . Subjects receive ongoing therapy contraindicate drug .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Phase 2</keyword>
	<keyword>Open-label</keyword>
	<keyword>Rollover</keyword>
	<keyword>Integrase Inhibitor</keyword>
	<keyword>Antiretroviral Agents</keyword>
	<keyword>Highly Active Antiretroviral Activity</keyword>
	<keyword>HAART</keyword>
	<keyword>HIV , HIV-1 , AIDS virus , Human Immunodeficiency Virus</keyword>
	<keyword>Acquired Immune Deficiency Syndrome Virus</keyword>
	<keyword>treatment experience</keyword>
</DOC>